Lakewood-Amedex Biotherapeutics Inc.

Lakewood-Amedex Biotherapeutics Inc. is a clinical-stage biotechnology company focused on developing antimicrobial products in the United States. The company's primary offerings include products from its Bisphosphocin class, which are a novel type of antimicrobial agents designed to combat infections by disrupting the membranes of microbes. Additionally, Lakewood-Amedex Biotherapeutics Inc. is developing Nu-3, a topical antimicrobial specifically intended for treating infected diabetic foot ulcers. The company, originally incorporated in 2006, was formerly known as Lakewood-Amedex Inc. and adopted its current name, Lakewood-Amedex Biotherapeutics, Inc., in June 2025. Its headquarters are located in University Park, Florida.